The success of definitive external beam radiotherapy (EBRT) for prostate cancer is often measured via control of prostate-specific antigen (PSA) levels.1,2 This occurs largely because PSA tests are inexpensive and widely available and provide an early indicator of treatment response. This evidence concerns the gene KLK3 and Familial prostate cancer.